Literature DB >> 8838015

Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1.

R Pearce-Pratt1, D M Phillips.   

Abstract

We have previously suggested that sulfated polysaccharides could be used in a vaginal formulation to inhibit infection by human immunodeficiency virus (HIV-1). This supposition was based on studies in which we developed and employed an in vitro model to simulate the mechanism of HIV-1 transmission during coitus. We found that adhesion of mononuclear cells to epithelia was the initial step in infection and speculated that blocking adhesion would prevent HIV-1 transmission. We observed that certain sulfated polysaccharides prevented adhesion of lymphoma cell lines to epithelial cell lines, which were derived from the genital tract, in concentrations of a few milligrams per milliliter; and we theorized that sulfated polysaccharides could thus be used as active ingredients in a topical "microbicide." In the present in vitro study, evidence is presented that a number of sulfated polysaccharides, including carrageenan, dextran sulfate, heparin, fucoidan, and pentosan polysulfate, are capable of blocking infection by mechanisms other than adhesion at concentrations of a thousand times lower than the dosages that are needed to block cell adhesion. One of these compounds, iota carrageenan, is capable not only of blocking infection of epithelia at concentrations of 1-2 micrograms, but of blocking adhesion to a far greater extent than the other sulfated polysaccharides tested. For this reason, as well as for considerations of safety, stability, and gelling properties, we suggest that iota carrageenan may be the best choice of the sulfated polysaccharides tested for use as a vaginal microbicide. The same in vitro model was employed to decipher the cell surface molecules involved in lymphocyte-to-epithelial adhesion. To accomplish this, we screened for the presence of cell adhesion molecules (CAMs), carbohydrates, proteoglycans, and carbohydrate-binding sites. HIV-1-infected lymphocytic cells expressed a CAM profile typical of activated, infected cells (e.g., HLA-DR+, CD4-, LFA-1+, ICAM-1+, LFA-3+, CD2+) whereas epithelia expressed few CAMs (LFA-3, ICAM-1, VLA-5, CD44, CD26, sLEX). Both cell types expressed heparan sulfate and chondroitin sulfate proteoglycans. A variety of sugars (mannose, fucose, galactose, Nac-galactosamine, Nac-glucosamine) were also present, but these cells expressed few carbohydrate-binding sites; lymphocytes bound beta-galactose. We were unable to block the adhesion with anti-CAM antibodies or with exogenous sugars. When enzymes were used against sulfated cell surface molecules, chondroitinase was found to block the adhesion. Our evidence suggests that this CAM-independent adhesion may be a lectin-glycosaminoglycan interaction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8838015     DOI: 10.1095/biolreprod54.1.173

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  33 in total

1.  Vaginal formulations of carrageenan protect mice from herpes simplex virus infection.

Authors:  V R Zacharopoulos; D M Phillips
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

Review 2.  Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.

Authors:  Jessica L Adams; Angela D M Kashuba
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2012-02-04       Impact factor: 5.237

3.  Expanded safety and acceptability of the candidate vaginal microbicide Carraguard® in South Africa.

Authors: 
Journal:  Contraception       Date:  2010-05-26       Impact factor: 3.375

4.  Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraception.

Authors:  Regine Sitruk-Ware; Vivian Brache; Robin Maguire; Horacio Croxatto; Narender Kumar; Sushma Kumar; Juan Carlos Montero; Ana Maria Salvatierra; David Phillips; Anibal Faundes
Journal:  Contraception       Date:  2007-04-18       Impact factor: 3.375

Review 5.  Vaginal drug delivery systems for HIV prevention.

Authors:  Lisa Cencia Rohan; Alexandra B Sassi
Journal:  AAPS J       Date:  2009-02-05       Impact factor: 4.009

Review 6.  Novel targets for antiretroviral therapy: clinical progress to date.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 7.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

Review 8.  Development of topical microbicides to prevent the sexual transmission of HIV.

Authors:  Robert W Buckheit; Karen M Watson; Kathleen M Morrow; Anthony S Ham
Journal:  Antiviral Res       Date:  2009-10-27       Impact factor: 5.970

9.  Renal epithelial cells produce and spread HIV-1 via T-cell contact.

Authors:  Maria Blasi; Bala Balakumaran; Ping Chen; Donatella R M Negri; Andrea Cara; Benjamin K Chen; Mary E Klotman
Journal:  AIDS       Date:  2014-10-23       Impact factor: 4.177

10.  Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells.

Authors:  Ping Chen; Benjamin K Chen; Arevik Mosoian; Thomas Hays; Michael J Ross; Paul E Klotman; Mary E Klotman
Journal:  J Am Soc Nephrol       Date:  2011-02-18       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.